Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Cancer treatment subsidiary sold to former CEO Augustine Cheung
February 9th, 2006
Celsion Corp. (CLN) announced that Augustine Cheung, PhD, its founder and chief scientific officer, resigned his positions as chief scientific officer and a member of the board of directors. The company also announced that Cheung has acquired 100% of the outstanding shares of Celsion (Canada), Ltd., a wholly owned subsidiary of Celsion Corp., which holds the license to and all the assets associated with Celsion's Adaptive phase d Array (APA) technology, for the purpose of further developing this technology for the treatment of breast cancer. The APA technology is licensed from Massachusetts Institute of Technology. Cheung has agreed to purchase the...
Source: Women's Health Weekly (2006-02-09)
|
